Pharmacy Benefits Administration - Maryland Medical Assistance Program and Pharmacy Benefits Managers
The bill proposes a shift in the reimbursement structure, which could lead to reduced disparities in compensation between independent pharmacies and larger corporate entities. By legislating minimum reimbursement levels, the measure attempts to stabilize the pharmacy market in Maryland, potentially encouraging more pharmacies to participate in the Medical Assistance Program. This move may ultimately benefit patients by ensuring their local pharmacies remain viable options for medication purchasing and management, particularly in underserved areas.
Senate Bill 895 introduces significant changes to the way pharmacy benefits are managed under the Maryland Medical Assistance Program. It mandates that pharmacy benefits managers (PBMs) reimburse pharmacies at a minimum level that matches the national average drug acquisition cost of generic products, plus a professional dispensing fee defined by the Maryland Department of Health. This adjustment aims to ensure that pharmacies receive fair compensation for the drugs they dispense, thereby enhancing the accessibility and affordability of medications for patients enrolled in the medical assistance program.
One point of contention surrounding SB 895 is the inclusion of provisions that exempt certain pharmacy types from the new reimbursement standards. Specifically, pharmacies that are owned by or have the same corporate affiliation as PBMs, as well as mail-order pharmacies, are excluded from the minimum reimbursement requirements. Critics argue that this could create an uneven playing field in the pharmacy market, allowing certain entities to thrive at the expense of independent pharmacies. These concerns highlight the tension between regulatory goals aimed at protecting local businesses and the existing frameworks that govern pharmacy benefits management.